TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 04/03/23

2023-04-03 03:51:40 ET Summary Sales of Takhzyro amounted to 44.1 billion Japanese yen in the 3rd quarter of 2022, an increase of 42.7% from the previous year. Takeda Pharmaceutical's revenue was $8,354 million in Q3 2022, showing phenomenal growth both year-on-year and quarter-on...

— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 3...

2023-03-30 11:28:34 ET A phase 4 study of Takeda Pharmaceutical Co.'s ( NYSE: TAK ) Entyvio met its primary endpoint in patients with ulcerative colitis. Results showed that at week 14, 31% of patients on Entyvio achieved remission from chronic or recurrent pouchitis ...

− The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus 10% Receiving Placebo. 1 − Superiority over Placebo Was Also D...

Takeda ( TSE:4502/NYSE:TAK ) announced that its Board of Directors today decided that it will propose a new candidate for independent external director at the 147 th Ordinary Meeting of Shareholders on June 28 th , 2023. The new candidate, Miki Tsusaka, will join the board effecti...

Expansion Contributes to the Company's Efforts Toward a Sustainable Global Plasma Supply to Support the Needs of People who Depend on Life-Saving Plasma Therapies . BioLife Plasma Services, part of the global biopharmaceutical company Takeda, today announced the opening of its 200 ...

2023-03-26 23:52:00 ET Summary Highlightll Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-o...

2023-03-24 04:44:46 ET Takeda Pharmaceutical ( NYSE: TAK ) said on Thursday that it will invest about ¥100B to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. The Japanese drugmaker noted that it was the company's largest eve...

2023-03-21 09:28:28 ET Ventyx Biosciences ( NASDAQ: VTYX ) traded higher pre-market Tuesday after Wells Fargo initiated its coverage with an Overweight recommendation citing an attractive entry point ahead of multiple catalysts over the next 12 – 18 months. The comp...

2023-03-20 06:45:56 ET TAK-279, an experimental tyrosine kinase 2 (TYK2) inhibitor developed by Takeda Pharmaceutical ( NYSE: TAK ), reached the primary and secondary endpoints in a mid-stage trial for patients with plaque psoriasis, the company announced. The Phase 2b study...